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RESEARCH ARTICLE
Metastatic Pancreatic Carcinoma and Experience with
FOLFIRINOX - a Cross Sectional Analysis From a Developing
Country
Muhammad Nauman Zahir1*, Adnan Abdul Jabbar2
Abstract
Background: Pancreatic cancer is the fourth leading cause of cancer related death with median survival
ranging from 3 to 6 months for metastatic disease. Palliative chemotherapy has been the backbone of treatment
in advanced stage and has evolved over time. Data pertaining to the disease are scarce from our part of the world
where treatment poses a significant challenge due to lack of resources. Materials and Methods: A retrospective
chart review was performed for all patients presenting with stage IV pancreatic carcinoma at a tertiary care
hospital in Karachi, Pakistan between January 2008 and December 2012. Data were collected using a pre-designed,
coded questionnaire looking at patient characteristics, treatment given and outcome. Results: 101 patients were
found to be eligible. Mean age was 56.7 ± 12.8 years, the male to female ratio was 2:1 and most patients had a
good performance status. More than half of the tumors were located in the head (57%, n=58) and almost all
were adenocarcinomas (95%, n=96). Some 58% (n=59) received first line chemotherapy of which 49% (n=29)
received gemcitabine-based regimens and 39% (n=23) received FOLFIRINOX. The median progression free
survival for gemcitabine based treatment was 2.9 months (IQR=1.6-5.6) as opposed to 7.3 months (IQR=4.5-9.2)
for FOLFIRINOX (P=0.02). Median overall survival was 4.9 months (IQR=2.3-9.5) for first line gemcitabine
based treatment and 10.5 months (IQR=7.0-13.2) for first line FOLFIRINOX therapy (P=0.002). Patients on
FOLFIRINOX had better survival across all subgroups. Inpatient admissions and dose reductions were more
frequent with FOLFIRINOX but the difference between the two regimens was not statistically significant.
FOLFIRINOX could be successfully administered as outpatient therapy to a number of patients. Conclusions:
FOLFIRINOX remains a suitable first line option in patients with metastatic pancreatic cancer with good
performance status even in a resource-poor country where diagnostic and supportive care facilities may be less
than optimal and cost is a limitation.
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Introduction
Pancreatic carcinoma is the fourth leading cause of
cancer related death in the Western world and the third
most common malignancy of the gastrointestinal tract
(Siegel, Naishadham and Jemal, 2013). The aggressive
nature of the disease coupled with advanced stage at
diagnosis in most cases, results in 5 year survival rate
of less than 5% (Jemal et al., 2005). Surgical resection
offers the only chance of cure but less than 15 to 20%
are resectable at initial diagnosis (Parvez and Dawood,
2003). Median survival ranges from 8 to 12 months for
locally advanced unresectable disease and 3 to 6 months
for patients presenting with metastasis (Siegel et al., 2013).
Chemotherapy has traditionally been the backbone
of treatment for advanced pancreatic carcinoma and has
evolved over time with gemcitabine based treatment
occupying the niche of “standard of care” until recently

(Di Marco et al., 2010). Gemcitabine therapy was
established as standard of care in advanced pancreatic
carcinoma back in 1997 (Burris et al., 1997) and since
then numerous studies have validated a median overall
survival of 6 months in advanced disease when the drug
has been used as a single agent (Conroy and Mitry, 2011).
Doublet chemotherapy has some benefit in response rate
(RR) and progression free survival (PFS) without any clear
difference in overall survival (OS) (Cunningham et al.,
2009). One promising emerging chemotherapeutic option
is the nab-Paclitaxel plus Gemcitabine combination which
has been shown to be effective (Von Hoff et al., 2013).
Improvement in the understanding of the molecular
biology of pancreatic cancer has led to an increased
effort to develop new management strategies. It is hoped
that these modalities will help improve the outcome of
advanced pancreatic carcinoma in the future (Valsecchi
et al., 2014).
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In May 2011, Conroy et al. published their experience
with FOLFIRINOX (combination chemotherapy
comprising oxaliplatin, irinotecan, folinic acid and
5-fluorouracil) where they reported a significant survival
benefit in comparison to Gemcitabine based chemotherapy
(Conroy et al., 2011). Although it has now been established
in the West as the preferred regimen for patients with
metastatic pancreatic cancer with good performance status
and a normal serum bilirubin level (Conroy et al., 2011),
no report from Asian trials or documented anecdotal
experience of its use from South Asia is available (Conroy
et al., 2013). A recently reported study has evaluated
XELOX as 2nd line therapy in an Asian population with
encouraging anti-tumor activity and manageable toxicity,
laying the foundation for further research exploring
FOLFIRINOX as a potential first line regimen in this
population (Bayoglui et al., 2014).
Pakistan with the sixth highest world population
and increasing burden of cancer including pancreatic
carcinoma has a similar trend, with most patients
presenting at an advanced stage. There is a paradigm
shift towards FOLFIRINOX as the preferred treatment
regimen in appropriately selected patients but no report
of the outcome, adverse events and challenges with the
treatment are available. Maintaining intravenous lines
for 5-FU infusion pump with high incidence of infection
due to poor hygiene, increased cost of FOLFIRINOX
over gemcitabine and poor educational background were
reasons for reservation of this regimen in our population.
Generally, there is dearth of data regarding experience with
FOLFIRINOX from South Asia where the documentation
of this experience is also of paramount importance because
of the genetic and cultural variability of the region from
the West.
This study was undertaken to estimate the burden of
stage IV pancreatic carcinoma at a major tertiary care
center in Karachi, Pakistan. We aimed to reflect upon the
management options used for metastatic disease at our
center, specifically highlighting differences in responses
between major treatment groups and the survival patterns
of these patients despite the local challenges.

Materials and Methods
Patients
Retrospective data was collected for adult patients
(≥16 years) with recently diagnosed (histopathologically
or cytologically confirmed) primary metastatic pancreatic
carcinoma presenting to the Aga Khan University Hospital
(AKUH), Karachi between January 1, 2007 and December
31, 2012. Patients were identified using the International
Classification of Diseases (ICD) coding system and the
cancer registry at AKUH. Patients had to be treatment
naive with no prior history of malignancy to be included
in the study.
Data was collected using a pre-designed and coded
questionnaire approved by the institutional Ethical Review
Committee. Details of demographics, symptomatology,
risk factors, diagnostic modalities used, histopathological
features, and outcome were collected for all patients.
Follow up records, data pertaining to therapies and
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dates of last contact were also recorded.
Statistical analysis
Statistical Package for Social Sciences (SPSS) version
19 was used to perform data analysis on 101 eligible
patients. Data was reported as mean ± standard deviation
for continuous variables and proportions and percentages
for categorical data. Continuous variables not following
the normal distribution were reported as medians along
with inter-quartile ranges.
Analysis was performed on the entire cohort
followed by a subgroup analysis according to the 2 major
chemotherapy regimens employed (Gemcitabine based
regimens vs. FOLFIRINOX). Categorical variables in the
subgroups were compared using the Pearson Chi Square
test or Fischer’s test while the Student’s t-test was used
to compare continuous data. Median PFS and median
OS were calculated in the two groups and Kaplan Meier
curves were generated. Median PFS in the two groups
was compared using the log-rank test while median OS
was compared using the Mann-Whitney test. P value less
than 0.05 was considered significant.

Results
Patients
101 eligible patients with metastatic pancreatic
carcinoma presented to our institution between January
1, 2007 and December 31, 2012 [Table 1]. The mean
age of the study population was 56.7±12.8 years and the
male to female ratio was 2:1. Most patients had a good
performance status at diagnosis (84%, n=85). More than
half of the tumors were located in the head of the pancreas
(57%, n=58) and almost all were adenocarcinomas (95%,
n=96). The most common clinical presentations included
abdominal pain (95%, n=96), weight loss (88%, n=89),
icterus (55%, n=55) and worsening of established type
2 Diabetes (40%, n=40). Deep venous thrombosis was a
presenting feature in 23% of patients (n=23).
On subgroup analysis, the baseline characteristics,
clinical presentations and laboratory parameters were
similar between the two groups divided according to the
two major chemotherapy regimens employed (Table 1).
The only notable difference was the presence of a larger
number of patients with an abnormal serum level of
CA-19-9 in the Gemcitabine group as compared to the
FOLFIRINOX group (72% vs. 48%). The relative absence
of patients with jaundice in the FOLFIRINOX group can
be attributed to the pharmacological limitation of using
hepatotoxic agents in patients with grossly abnormal
bilirubin levels (11).
Treatment
Almost half of the study population (42%, n=42)
presented at a stage where chemotherapeutic intervention
was not possible and received palliative surgical
intervention (n=10) or comfort care (n=32) . Of the
remaining 59 patients who were clinically suitable to
receive first line chemotherapy, 49% (n=29) received
Gemcitabine based regimens, 39% (n=23) received
FOLFIRINOX whereas 12% (n=7) were treated with other
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chemotherapeutic regimens.
The median number of cycles received by patients in
the Gemcitabine group were 4 (IQR=3-7.5) as opposed
to 16 (IQR=9-19) in the FOLFIRINOX group (p<0.001).
This corresponded to a median duration of 12.8 weeks
(IQR=7.4-25.1) for patients on Gemcitabine versus 35.8
weeks (IQR=21.6-41.6) for patients in the FOLFIRINOX
group (p<0.001).
The most common grade 3 and 4 side effects with first
line Gemcitabine were elevated Alanine transaminase
(ALT) 14% (n=4), febrile neutropenia 10% (n=3) and
thrombocytopenia 7% (n=2) whereas for first line
FOLFIRINOX, these were febrile neutropenia (22%, n=5),
thrombocytopenia (22%, n=5), peripheral neuropathy
(9%, n=2) and diarrhea (9%, n=2) [Table 2].
Although the frequency of side effects, dose reductions
and patients requiring inpatient admissions were more
common in the group receiving FOLFIRINOX, the
difference between the 2 groups was not found to be
statistically significant [Table 2].

Only 18 patients (18%) received any second-line
chemotherapy out of which 7 (39%) received Gemcitabine
based therapy, 5 (28%) received Capecitabine based
treatment and 4 (22%) were given FOLFIRINOX. The
number of patients receiving second line chemotherapy
was too small for meaningful analysis.
Outcome
At 6 months followup, only 24% of patients (n=24)
from the entire cohort were alive. All 42 patients who had
not received any chemotherapy had died. At the one year
interval the percentage of surviving patients had dropped
to an even more dismal 13% (n=13).
On subgroup analysis according to the two major
chemotherapy groups, only 24% (n=7) patients in
Gemcitabine group were alive as opposed to 61% (n=14)
on FOLFIRINOX at the 6 month interval (p<0.001).
This difference in overall survival remained statistically
significant at 1 year followup as well (17% Gemcitabine
vs. 26% FOLFIRINOX, p=0.008).

Table 1. Baseline Characteristics of the Study Population
Variables

All metastatic
pancreatic cancers n=101

1st line Gemcitabine
based treatment n=29

1st line FOLFIRINOX
n=23

Age, Mean (SD)
56.7 (12.8)
54.4 (12.4)
51.9 (10.5)
≤40 (%)
13 (12.9)
4 (13.8)
4 (17.4)
>40 (%)
88 (87.1)
25 (86.2)
19 (82.6)
Gender, Male (%)
69 (68.3)
19 (65.5)
14 (60.9)
ECOG Performance Status			
0 to 2
85 (84.2)
28 (96.6)
23 (100)
3 to 4
16 (15.8)
1 (3.4)
Site of Tumor			
Head (%)
58 (57.4)
14 (48.3)
13 (56.5)
Body/tail (%)
43 (42.6)
15 (51.7)
7 (43.5)
Diagnosis			
Adenocarcinoma (%)
96 (95)
29 (100)
22 (95.7)
Other (%)
5 (5)
1 (4.3)
Symptoms			
Abdominal Pain (%)
96 (95)
27 (93.1)
22 (95.7)
Weight Loss (%)
89 (88.1)
26 (89.7)
17 (73.9)
Jaundice (%)
55 (54.5)
14 (48.3)
10 (43.5)
Worsening of Diabetes (%)
40 (39.6)
9 (31)
9 (39.1)
DVT (%)
23 (22.8)
6 (20.7)
3 (13.0)
Laboratory Parameters			
Total bilirubin > 2 (%)
48 (47.5)
12 (41.4)
4 (17.4)
Normal CA-19-9
27 (26.7)
8 (27.6)
12 (52.2)

Table 2. Grade 3-4 Adverse Effects, Dose Reduction and In-Patient Admission Data
Variables
Major Side Effects of Chemotherapy
Thrombocytopenia (%)
Febrile Neutropenia (%)
Peripheral Neuropathy (%)
Diarrhea (%)
Mucositis (%)
AKI (%)
Elevated ALT (%)
Dose Reduction Needed (%)
Admission Required (%)

All metastatic pancreatic
cancers receiving 1st line
chemotherapy (n=52)
7 (13.5)
8 (15.4)
2 (3.8)
3 (5.8)
1 (1.9)
2 (3.8)
5 (9.6)
7 (13.4)
15 (28.8)

1st line Gemcitabine
based treatment
(n=29)

1st line
FOLFIRINOX
(n=23)

2 (6.9)
3 (10.3)
0 (0)
1 (3.4)
0 (0)
1 (3.4)
4 (13.8)
2 (6.9)
8 (27.6)

5 (21.7)
6 (21.7)
7 (21.7)
8 (21.7)
9 (21.7)
10 (21.7)
11 (21.7)
5 (21.7)
7(30.4)
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Table 3. Subgroup and Stratified Subgroup Analysis
Variables

Median survival
All cases (n=101)
Months (IQR)

Age
Gender
ECOG
Total Bilirubin
CA-19-9
Site of tumor

Entire cohort
≤40
>40
Male
Female
ECOG 0-2
ECOG 3-4
< 2 mg/dl
≥ 2mg/dl
Normal
Abnormal
Head
Body/tail

4.7 (2.1-8.6)
6.9 (3.0-11.2)
4.6 (1.9-8.3)
4.1 (1.8-8.0)
4.1 (1.8-8.0)
5.3 (2.4-10.4)
1.8 (1.2-2.5)
5.4 (2.2-10.1)
3.2 (1.8-7.3)
10.0 (2.5-15.3)
3.8 (1.8-6.4)
5.1 (2.3-10.1)
3.2 (1.7-8.4)

Median Survival
Gemcitabine (n=29)
Months (IQR)

4.9 (2.3-9.5)
7.9 (3.0-15.4)
4.9 (2.3-7.9)
5.1 (4.3-11.3)
2.2 (1.2-5.1)
4.9 (2.4-10.0)
2.3 (n=1)
4.2 (2.2-5.0)
9.0 (4.8-15.5)
4.9 (2.3-7.9)
4.7 (2.5-15.5)
5.7 (4.7-11.9)
2.5 (1.4-6.2)

Median Survival
FOLFIRINOX (n=23)
Months (IQR)

10.5 (7.0-13.2)
7.1 (2.8-10.2)
10.8 (7.2-15.1)
10.6 (6.3-13.7)
10.6 (6.3-13.7)
10.5 (7.0-13.2)
10.4 (7.0-11.9)
13.0 (6.5-16.6)
8.8 (6.2-11.1)
13.0 (6.5-16.6)
10.8 (6.2-15.2)
10.3 (7.2-11.6)

Stratified subgroup analysis
A stratified subgroup analysis was carried out to look
for the effect of age, gender, ECOG performance status,
total bilirubin, CA 19-9 and site of tumor on outcome
within each therapeutic sub-group. No statistically
significant contribution of these variables was noted on
outcome during analysis [Table 3]. It is possible that a
difference may not have been elucidated due to the small
number of patients in the sub-groups.

Discussion
Figure 1. Kaplan-Meier Curve for Progression Free
Survival (PFS)

Figure 2. Kaplan-Meier Curve for Overall Survival
(OS)
The median PFS for patients on first line Gemcitabine
based chemotherapy was 2.9 months (IQR=1.6-5.6) as
opposed to 7.3 months (IQR=4.5-9.2) for patients on first
line FOLFIRINOX (p=0.003) [Figure 1].
The median OS was 4.9 (IQR=2.3-9.5) months for
the Gemcitabine and 10.5 (IQR=7.0-13.2) months for the
FOLFIRINOX group (p=0.002) [Figure 2]. The median
OS for the entire cohort was 4.7 months (IQR=2.1-8.6).
Patients on FOLFIRINOX had better survival across
all subgroups when compared with patients who had
received Gemcitabine [Table 3].

6004

Asian Pacific Journal of Cancer Prevention, Vol 16, 2015

Although small, our study is the first describing
experience with FOLFIRINOX in the South Asian
population. The results from our study reiterate a significant
survival benefit with FOLFIRINOX when compared to
gemcitabine based treatment. The approximate doubling
of both PFS (7.3 vs. 2.9 months) and OS (10.5 vs. 4.9
months) with FOLFIRINOX vs. Gemcitabine based
therapy mirrors the results of the pivotal paper by Conroy
et al. (2011) and is similar to the OS reported in other
Western studies (Peddi et al., 2012; Gunturu et al., 2013).
The survival at one year in the FOLFIRINOX group in
our study was lower than the one reported in Conroy’s
study (48% vs. 26%) which may be secondary to the lower
number of patients in our study.
These results suggest that the therapeutic benefits
of FOLFIRINOX over Gemcitabine hold true for the
Asian population as well as in our clinical setting. This
coupled with the observation that FOLFIRINOX confers
approximately the same benefit across all patient subgroups further adds to the value of the regimen [Table 3].
The only subgroup of patients which showed an inferior
survival amongst patients receiving FOLFIRINOX in our
study was that of <40 year olds. However no definitive
inference can be made due to the small number of patients
in this subgroup.
One may argue that a higher proportion of patients in
the FOLFIRINOX group in our study had a normal CA
19-9 at presentation and may have been responsible for
the better prognosis seen with this chemotherapy regimen
as it has been reported to be a predictor of better survival
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in chemo-naive patients (Berger et al., 2004; Waraya et
al., 2009; Ballehaninna and Chamberlain, 2012). This
hypothesis is however refuted by the fact that the survival
benefit inferred by the normal serum CA 19-9 levels in
chemo-naive metastatic pancreatic carcinoma patients,
was lost when patients received any chemotherapy [Table
3]. This is an interesting observation though and one which
can be further explored.
Another interesting observation in the group which
received first line Gemcitabine was patients with a raised
bilirubin level and those with tumors of the head of the
pancreas fared better than those with normal bilirubin and
tumors elsewhere in the pancreas. One may speculate that
patients with tumors of the head of the pancreas would
more likely present early secondary to extrinsic biliary
obstruction and jaundice, resulting in better outcome, but
in the end these were all stage IV patients.
One of the major limitations of FOLFIRINOX has
been the higher frequency of adverse effects observed
with the regimen (Ko 2011). The skepticism associated
with FOLFIRINOX use has somewhat been dispelled
with the use of the regimen in several studies in the West
which despite indicating a clearly significant increase
in adverse events with its use, also prove that these are
easily manageable with appropriate therapy (Conroy
et al., 2011; Peddi et al., 2012; Gunturu et al., 2013). A
similar trend was seen in our study where although the
frequency of grade 3 and 4 side effects were higher in the
FOLFIRINOX group, they were not significantly different
from the Gemcitabine group and were manageable with
adequate treatment when they did occur. Also patients
received more weeks of treatment in FOLFININOX
group compared to Gemcitabine based chemotherapy.
This highlights the fact that the regimen is reasonably well
tolerated in our population and in light of the statistically
significant survival benefit conferred; the slightly
unfavorable toxicity profile may well be acceptable to
patients and clinicians worldwide.
Experimentation with modifications to the
FOLFIRINOX regimen have been carried out to reduce
toxicity without compromising on the efficacy and a recent
study by Mahaseth et al. which deleted 5-FU bolus from the
regimen while employing routine use of GCSF, has shown
to be better tolerated while achieving disease control in
most patients (Mahaseth et al., 2013). Researchers
elsewhere have employed reduced median relative doses
of FOLFIRINOX but have managed to maintain efficacy
(Gunturu et al., 2013). These modifications may eventually
result in further improving the toxicity profile of the
regimen making it more palatable.
An important factor dictating the acceptance of
FOLFIRINOX in a resource poor country like Pakistan
is the cost associated with its use. Although the regimen
has been proclaimed as cost-effective (Mahaseth et
al., 2013), the substantial out of pocket disbursement
necessary in our country has the potential of limiting its
use to the affluent only. An estimate of the difference in
cost calculated at the end of six weeks of therapy between
the two regimens indicates FOLFIRINOX to be twice as
expensive as Gemcitabine based treatment ($1524 vs.
$762). Until recently FOLFIRINOX was given solely

as inpatient treatment, but with the recent availability
of outpatient infusion pumps we have transitioned the
regimen to an out-patient setting without a distinct increase
in complication rates or side effects in an economically
transitioning country with less than optimal hygienic
conditions. This change has further reduced the cost of
regimen and it is possible that modifications in the regimen
itself (e.g. deletion of 5-FU bolus) may make it even more
affordable in the near future.
Our study has certain limitations. One of the most
imminent limitations is the retrospective nature of
collection of data through hospital records. This has the
potential for incomplete data collection due to missing
information in the charts. In our defence, most of our
variables are laboratory investigations, treatment related
variables and survival data which are documented in
detail at our institution and hence are less likely to create
bias because of incomplete information. Secondly, this is
a single center study and it can be argued that the results
cannot be generalized to the local population at large. The
fact that metastatic pancreatic carcinoma is a rare disease
and Aga Khan University is the major tertiary care center
catering to patients from all over the country, we can
speculate to generalize the result as the numbers in each
individual subgroup seems reasonable. Finally, an element
of bias that could not be controlled was the difference in
calendar time for receiving the two major chemotherapy
regimens. Gemcitabine based chemotherapy was solely
prescribed till 2 years ago when it was the standard of
care whereas FOLFIRINOX became practice recently.
This difference has the potential of skewing the survival
results in favor of FOLFIRINOX as part of the survival
benefit may be due to improved supportive care and other
secular trends over time.
In conclusion, our study attempts to fill the void of
information currently present pertaining to pancreatic
cancer in our country. It highlights the baseline
characteristics and outcomes of patients presenting with
metastatic disease to our institution. To the best of our
knowledge this is the first study from South Asia narrating
experience with FOLFIRINOX and hence it is also the
first to compare the regimen with Gemcitabine based
chemotherapy.
We strongly believe that the results of this study
should be able to instill enough confidence in physicians
in the region to use the regimen as first line treatment
in appropriately selected patients even in a resource
challenged country such as ours.
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